Key facts
- Gameto’s last known valuation is $243.0M (Aug 2025).
- It has raised $127.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($44.0M) in Aug 2025.
- Notable investors include FJ Labs, Insight Partners (New York), Gaingels, RA Capital Management, Lux Capital — 49 tracked in total.
- Gameto has filed 2 Form Ds with the SEC since 2024, most recently Aug 2025 ($44.0M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 49 names
- ·Watchlist + deal alerts for Gameto
Funding rounds
2 roundsAbout Gameto
Operator of a biotechnology company intended to solve diseases of the female reproductive system. The company's platform uses proprietary combinations of transcription factors to generate engineered ovarian cell lines that mimic the functions of endogenous cells, producing and responding to all hormones, enabling women to solve the problem of accelerated ovarian aging.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2020
- Employees
- 47
- Website
- gametogen.com/
- Ownership
- Privately Held (backing)
Gameto doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gameto shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gameto in its N-PORT filings yet. We sweep new filings monthly.